Belite Bio, Inc (BLTE)
Nasdaq · Healthcare · Biotechnology
$159.18−0.24%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $6.4B
- Forward P/E
- 70.4
- 52-week range
- $75.95 – $200.00
- 52-week change
- +104.30%
- EPS (trailing)
- −$2.74
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Net income
- −$77.6M
- Diluted EPS
- −$2.31
- Free cash flow
- −$37.1M
From the company’s annual report on SEC EDGAR.
About Belite Bio, Inc
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Headquarters: San Diego, United States · 41 employees · belitebio.com